A Disease State Fingerprint for Evaluation of Alzheimer's Disease

被引:70
|
作者
Mattila, Jussi [1 ]
Koikkalainen, Juha [1 ]
Virkki, Arho [1 ]
Simonsen, Anja [2 ,3 ]
van Gils, Mark [1 ]
Waldemar, Gunhild [2 ,3 ]
Soininen, Hilkka [4 ]
Lotjonen, Jyrki [1 ]
机构
[1] VTT Tech Res Ctr Finland, FIN-33101 Tampere, Finland
[2] Copenhagen Univ Hosp, Dept Neurol, Sect 2082, Copenhagen Memory Clin, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Memory Disorders Res Grp, Copenhagen, Denmark
[4] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; automatic; biomarkers; computer-assisted; decision making; information processing; projections and predictions; MILD COGNITIVE IMPAIRMENT; DEMENTIA; DIAGNOSIS; PREDICTION; CONVERSION; MARKERS; EUROPE; COHORT; MRI; MCI;
D O I
10.3233/JAD-2011-110365
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Diagnostic processes of Alzheimer's disease (AD) are evolving. Knowledge about disease-specific biomarkers is constantly increasing and larger volumes of data are being measured from patients. To gain additional benefits from the collected data, a novel statistical modeling and data visualization system is proposed for supporting clinical diagnosis of AD. The proposed system computes an evidence-based estimate of a patient's AD state by comparing his or her heterogeneous neuropsychological, clinical, and biomarker data to previously diagnosed cases. The AD state in this context denotes a patient's degree of similarity to a previously diagnosed disease population. A summary of patient data and results of the computation are displayed in a succinct Disease State Fingerprint (DSF) visualization. The visualization clearly discloses how patient data contributes to the AD state, facilitating rapid interpretation of the information. To model the AD state from complex and heterogeneous patient data, a statistical Disease State Index (DSI) method underlying the DSF has been developed. Using baseline data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ability of the DSI to model disease progression from elderly healthy controls to AD and its ability to predict conversion from mild cognitive impairment (MCI) to AD were assessed. It was found that the DSI provides well-behaving AD state estimates, corresponding well with the actual diagnoses. For predicting conversion from MCI to AD, the DSI attains performance similar to state-of-the-art reference classifiers. The results suggest that the DSF establishes an effective decision support and data visualization framework for improving AD diagnostics, allowing clinicians to rapidly analyze large quantities of diverse patient data.
引用
收藏
页码:163 / 176
页数:14
相关论文
共 50 条
  • [21] Quantitative evaluation of Alzheimer's disease
    Duchesne, S.
    Frisoni, G. B.
    MEDICAL IMAGING 2009: COMPUTER-AIDED DIAGNOSIS, 2009, 7260
  • [22] Evaluation of anosognosia in Alzheimer's disease
    Turro-Garriga, Oriol
    Lopez-Pousa, Secundino
    Vilalta-Franch, Joan
    Garre-Olmo, Josep
    REVISTA DE NEUROLOGIA, 2012, 54 (04) : 193 - 198
  • [23] A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer's disease
    Feng, Xinyang
    Provenzano, Frank A.
    Small, Scott A.
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [24] Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease
    Sluimer, Jasper D.
    van der Flier, Wiesje M.
    Karas, Giorgos B.
    van Schijndel, Ronald
    Barnes, Josephine
    Boyes, Richard G.
    Cover, Keith S.
    Olabarriaga, Silvia D.
    Fox, Nick C.
    Scheltens, Philip
    Vrenken, Hugo
    Barkhof, Frederik
    EUROPEAN RADIOLOGY, 2009, 19 (12) : 2826 - 2833
  • [25] Tear Biomarkers and Alzheimer's Disease
    Kastelan, Snjezana
    Bras, Marijana
    Pjevac, Neda
    Bakija, Ivana
    Tomic, Zora
    Pjevac Keleminic, Nada
    Antunica, Antonela Gverovic
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [26] Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance
    Ewers, Michael
    Walsh, Cathal
    Trojanowski, John Q.
    Shaw, Leslie M.
    Petersen, Ronald C.
    Jack, Clifford R., Jr.
    Feldman, Howard H.
    Bokde, Arun L. W.
    Alexander, Gene E.
    Scheltens, Philip
    Vellas, Bruno
    Dubois, Bruno
    Weiner, Michael
    Hampel, Harald
    NEUROBIOLOGY OF AGING, 2012, 33 (07) : 1203 - +
  • [27] Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative
    Fowler, Mackenzie E.
    Triebel, Kristen L.
    Cutter, Gary R.
    Schneider, Lon S.
    Kennedy, Richard E.
    JOURNAL OF ALZHEIMERS DISEASE, 2020, 76 (02) : 691 - 701
  • [28] Validation of the Alzheimer's disease-resemblance atrophy index in classifying and predicting progression in Alzheimer's disease
    He, Qiling
    Shi, Lin
    Luo, Yishan
    Wan, Chao
    Malone, Ian B.
    Mok, Vincent C. T.
    Cole, James H.
    Anatuerk, Melis
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [29] Resting-state electroencephalographic biomarkers of Alzheimer's disease
    Cecchetti, Giordano
    Agosta, Federica
    Basaia, Silvia
    Cividini, Camilla
    Cursi, Marco
    Santangelo, Roberto
    Caso, Francesca
    Minicucci, Fabio
    Magnani, Giuseppe
    Filippi, Massimo
    NEUROIMAGE-CLINICAL, 2021, 31
  • [30] Current State of Saliva Biomarkers for Aging and Alzheimer's Disease
    Francois, Maxime
    Bull, Caroline F.
    Fenech, Michael F.
    Leifert, Wayne R.
    CURRENT ALZHEIMER RESEARCH, 2019, 16 (01) : 56 - 66